Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has appointed two senior executives to the leadership team. Filip Dubovsky, M.D., MPH, FAAP, has been appointed senior vice president and chief medical officer, where he will oversee Novavax’ medical and clinical affairs and related activities. Novavax also appointed Silvia Taylor, MBA, as senior vice president, investor relations and corporate affairs, overseeing Novavax’ invest...